<DOC>
	<DOCNO>NCT01774747</DOCNO>
	<brief_summary>Double-blind , placebo-controlled , multiple ascend oral dose evaluation safety , tolerability , pharmacokinetics DSP 1053 metabolite healthy subject subject major depressive disorder</brief_summary>
	<brief_title>A Multiple Ascending Oral Dose Evaluation Safety , Tolerability , Pharmacokinetics DSP-1053 Its Metabolites Healthy Subjects Subjects With Major Depressive Disorder</brief_title>
	<detailed_description>This study conduct single site double-blind , placebo-controlled , mulitple ascend oral dos evaluation safety , tolerability , pharmacokinetics DSP-1053 metabolites healthy subject Major depressive disorder minimumally intolerated dose reach healthy subject</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Healthy Subjects : Be able understand willing sign Informed Consent Form , capable provide write authorization use disclosure protect health information per requirement 45 Code Federal Regulations ( CFR ) 164.508 ( Health Information Portability Accountability Act [ HIPAA ] ) . Be healthy male female subject 18 50 year age ( inclusive ) . Have BMI 18 33 kg/m2 . Have clinically relevant abnormal laboratory value screen Day 1 . Have clinically relevant finding vital sign measurement screen checkin . Have clinically relevant finding physical examination screen check . Have negative urine drug abuse test ( cannabinoids , barbiturate , cocaine , opiates , benzodiazepine , phencyclidine , methadone ) negative cotinine test screen check . Have negative alcohol breath test screen check . Have negative Hepatitis B surface antigen , Hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody test screen . Have normal hepatic function [ aspartate transaminase ( AST ) , bilirubin , alanine transaminase ( ALT ) ] renal function ( creatinine clearance great 80 mL/min assess Cockcroft Gault equation use serum creatinine ) screen Day 1 . Be females childbearing potential : negative serum hCG pregnancy test screen Day 1 ; willing breastfeed Day 5 90 day discharge study site ; Be female : unable child ( eg , post menopausal , tubal ligation , hysterectomy ) OR willing remain abstinent ( engage sexual intercourse ) check 90 day discharge study site . OR willing use effective method doublebarrier birth control ( eg , partner use condom female use diaphragm , contraceptive sponge , spermicide , intrauterine device ) checkin 90 day discharge study site . Be male : sterile willing remain sexually abstinent use effective method birth control ( eg , condom ) checkin 90 day discharge study site . AND agree donate sperm study 90 day discharge study site . Refrain strenuous physical activity 48 hour prior checkin discharge study site . Agree remain housed study site clinical confinement study return visit require additional safety PK assessment . Agree consume study meal per protocol . Subjects MDD : In addition inclusion criterion mention healthy subject , follow inclusion criterion apply subject MDD : Have diagnosis MDD define Diagnostic Statistical Manual Mental Disorders Fourth Edition ; Text Revision ( DSM IV TR ) criterion confirm Mini International Neuropsychiatric Interview ( MINI ) diagnostic interview . This diagnosis confirm psychiatrist psychologist . The diagnosis supplement ( possible ) confirmation chart record discussion treat healthcare professional reliable informant . Diagnosis make psychologist must review psychiatrist . The subject ' current major depressive episode must â‰¥ 4 week &lt; 2 year duration . Are able washout prior antidepressant therapy Day 1 , able forego psychotherapy Day 1 Day 10 , inclusive , deem clinically stable PI 's assessment . May comorbid anxiety disorder generalize anxiety disorder ( GAD ) social phobia obsessive compulsive disorder ( OCD ) long comorbid anxiety disorder major source impairment . Have stable living arrangement least 3 month prior check agree return similar living arrangement discharge . This criterion mean exclude subject temporarily leave stable living environment . Such subject remain eligible participate study . Chronically homeless subject enrol . The Medical Monitor consult individual case need . Healthy Subjects Significant history clinical manifestation acute chronic condition opinion PI , would limit subject 's ability complete and/or participate study : metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , urological , neurological , psychiatric disorder ; drug hypersensitivity ; stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug ( appendectomy , hernia repair , and/or cholecystectomy allow discretion PI ) ; abnormal ECG , , PI 's opinion , clinically significant ; know suspect alcohol substance abuse/ dependence within one year prior check ; movement disorder include tremor ; lifetime family history seizure febrile seizure . Poor peripheral venous access . Does tolerate venipuncture . Donation blood 28 day prior screen study completion , inclusive . Receipt blood product within 2 month prior check . Any acute chronic condition , opinion PI , would limit subject 's ability complete and/or participate clinical study . Female subject menstrual dysfunction . Considered PI imminent risk suicide injury self , others , property . Subject answer `` yes '' `` Suicidal Ideation '' Items 4 5 CSSRS screening . Subjects , history , smoke use tobacco product within 60 day screen study follow . Consumption food beverage contain alcohol , grapefruit , caffeine within 72 hour prior check discharge study site , unless deem acceptable PI . Participation investigational study drug trial receipt investigational study drug occur within 5 half live 3 month prior checkin , whichever longer . Taken drug ( ) know clinically relevant cytochrome P450 2D6 ( CYP2D6 ) , cytochrome P450 3A4 ( CYP3A4 ) inhibitors inducer within 28 day prior first DSP 1053 dose study conduct follow . Taken antihistamine within 14 day prior checkin study . Family history prolong QT interval ( QTc ) prolongation . Subjects , history , risk bleed abnormal prothrombin value currently use anticoagulant treatment ( warfarin ) Clinically important folic acid B12 abnormality detect within 3 month screen . Use prescription medications/products within 14 day prior check unless deem acceptable PI . Subjects MDD Except Exclusion Criterion 18 mention healthy subject exclusion criterion apply addition follow exclusion criterion apply subject MDD : History bipolar disorder ( I II ) , schizophrenia , schizoaffective disorder , eat disorder , obsessive compulsive disorder . Any current Axis I disorder major depressive disorder focus treatment . Substance alcohol abuse last 3 month substance alcohol dependence last 12 month . Concomitant psychotropic medication , include herbal . Significant risk violent behavior significant risk suicidal behavior base history PI 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>